XGN earnings: real EPS beat/miss history, analyst consensus Buy, P/E -5.49. Updated 2026-07-23.
Exagen (XGN) Research Hub
Exagen (XGN) trades on NASDAQ, US in the Healthcare (Medical - Diagnostics & Research) sector. As of 2026-09-11, shares last closed at 7.03 USD (-3.83%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -5.49, market cap 0.12B. This hub links to the full technical, earnings and options research available for XGN.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Medical - Diagnostics & Research) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 7.03 USD (-3.83%) |
| 52-week range | 4.09 USD – 7.99 USD |
| Trend regime | Range |
| 14-day RSI | 52.2 (Neutral) |
| Trailing P/E | -5.49 |
| Market cap | 0.12B |
| Dividend yield | 0.00% |
Available research for XGN
Covered Call on XGN: how it works, illustrative setup around the real 7.03 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on XGN: how it works, illustrative setup around the real 7.03 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on XGN: how it works, illustrative setup around the real 7.03 USD price, max profit/loss, breakeven and when to use it. Educational.
XGN technical analysis: range, last 7.03 USD, RSI 52.2, 52w range 4.09 USD–7.99 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is XGN in?
Exagen (XGN) is classified under Healthcare (Medical - Diagnostics & Research), listed on NASDAQ, US.
Is XGN in an uptrend or downtrend?
As of 2026-09-11, XGN is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is XGN's trailing P/E ratio?
XGN's trailing P/E is -5.49, with a market cap of 0.12B. See the earnings research page for full valuation detail.